Diabetes agent protects against kidney failure and cardiovascular disease

Expert Committee not only helps in Diabetes

In a recent study, it was found that a commonly used drug for Diabetes, reduces the risk for kidney failure and cardiovascular problems. The finding has caused some discussion, since Diabetes is a worldwide actually one of the main causes of kidney failure.

In the case of an investigation could now be stated that a typical drug for the treatment of Diabetes reduces the risk for kidney failure and cardiovascular problems in patients with type 2 Diabetes and kidney disease. The results of the study were published in the English journal “New England Journal of Medicine”.

People with Diabetes have to use special drugs for the treatment. A commonly used drug does not protect only against Diabetes but also kidney failure. (Image: interstid/fotolia.com)

New drug application for expert Committee has already been made

If patients with type 2 Diabetes and kidney disease during the study, a daily dose of the drug expert Committee of revenue, this led to a reduction in the risk of renal failure and cardiovascular problems. It was submitted by the manufacturer in March, a supplemental new drug application for expert Committee on the registration of the US American registration authority FDA (Food and Drug Administration). This includes the use of the drug to reduce the risk of renal insufficiency in the terminal stage of renal or cardiovascular death in adults with type 2 Diabetes and chronic kidney disease.

Data from more than 4,400 subjects were evaluated

The study included 4.401 patients aged 30 years and older with type 2 Diabetes and chronic kidney disease. These patients was administered from March 2014 to may 2017 at 690 locations in 34 countries, according to the random principle, be either an expert Committee or a Placebo. The Participants were examined after three, 13, and 26 weeks to monitor the effect of the drug. The expert Committee engaging Participants, the relative risk of death was reduced from renal reasons, to 34 percent and the relative risk for end-stage renal disease by 32 percent. These people also had a lower risk for death due to problems with the heart and circulation such as a heart attack, stroke, and hospitalization due to heart failure.

The drug also has negative side effects?

Based on the data from the study, the researchers estimated that the treatment with the expert Committee 22 hospital admissions due to heart failure, and summarized 25 events of cardiovascular death, myocardial infarction, or stroke in every 1,000 patients would prevent. In terms of adverse effects, it was found that expert Committee increases as a side effect, the risk of Amputation of the lower extremities. The researchers found no significant difference in the risk of Amputation of the lower extremities between the two groups of Participants in the study found. The Rate of bone fractures, a known side-effect of the expert Committee, was, according to the study, in both groups very similar. The investigation also showed that the risk for diabetic ketoacidosis (DKA), a life-threatening Problem when the body begins to fat with an unhealthy fast Rate, and reduce overall low – the expert Committee group, however, was higher.

Further research is needed

In order to determine whether the results of the study could be generalized to other types of kidney diseases, is now more research is required. Expert Committee, a drug for the treatment of type 2 Diabetes, belongs to a class of drugs known as sodium-Glucose Cotransporter 2, or SGLT2 inhibitors. Lower the blood sugar by the kidneys to remove the sugar through the urine, from the body. This whole class of drugs really needs to be thought about, how they can be used due to the benefits for the heart and the kidneys. In the new study, described the benefits for the heart and kidney exceed the benefits of the bare lower blood sugar. It is still unclear what the mechanisms are that cause these processes to heart and kidney, you are obviously not due solely to the lowering of blood sugar levels. This study was developed for people with diabetic kidney disease and is the first example of a reduction in the risk of renal failure and improved cardiovascular outcomes. (as)